Vicapsys Life Sciences Inc
Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and … Read more
Vicapsys Life Sciences Inc (VICP) - Total Liabilities
Latest total liabilities as of March 2025: $3.07 Million USD
Based on the latest financial reports, Vicapsys Life Sciences Inc (VICP) has total liabilities worth $3.07 Million USD as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Vicapsys Life Sciences Inc - Total Liabilities Trend (2008–2024)
This chart illustrates how Vicapsys Life Sciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Vicapsys Life Sciences Inc Competitors by Total Liabilities
The table below lists competitors of Vicapsys Life Sciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
All Cosmos Bio-Tech Holding Corp
TW:4148
|
Taiwan | NT$698.22 Million |
|
GIIR Inc
KO:035000
|
Korea | ₩282.88 Billion |
|
Helios Energy Limited
PINK:HLEGF
|
USA | $1.73 Million |
|
Tae Kyung Ind
KO:015890
|
Korea | ₩389.24 Billion |
|
Surge Battery Metals Inc
PINK:NILIF
|
USA | $590.00K |
|
BMS Celik Hasir Sanayi ve Ticaret AS
IS:BMSCH
|
Turkey | TL869.65 Million |
Liability Composition Analysis (2008–2024)
This chart breaks down Vicapsys Life Sciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 522.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vicapsys Life Sciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vicapsys Life Sciences Inc (2008–2024)
The table below shows the annual total liabilities of Vicapsys Life Sciences Inc from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.89 Million | +47.05% |
| 2023-12-31 | $1.97 Million | +92.44% |
| 2022-12-31 | $1.02 Million | +42.86% |
| 2021-12-31 | $715.96K | -16.09% |
| 2020-12-31 | $853.22K | +115.20% |
| 2019-12-31 | $396.48K | -62.24% |
| 2018-12-31 | $1.05 Million | +1.98% |
| 2017-12-31 | $1.03 Million | -79.26% |
| 2009-12-31 | $4.96 Million | +94.60% |
| 2008-12-31 | $2.55 Million | -- |